# Lp(a)-spiegels stijgen tijdens menopauze — herhaalde bepaling nodig bij vrouwen met tussenliggende baseline

*geplaatst 2026-09-25 · Cholesterol · European journal of preventive cardiology · doi 10.1093/eurjpc/zwag496 · https://hartvaat.nl/2026/09/17/lp-a-spiegels-stijgen-tijdens-menopauze-herhaalde-bepaling-nodig-bij-vrouwen-met/*

Een cohortstudie onder 4.562 vrouwen uit de UK Biobank toont aan dat de overgang naar de menopauze de lipoproteïne(a)-spiegels (Lp(a)) significant kan verhogen, vooral bij vrouwen met een tussenliggende baseline-waarde (75–125 nmol/L). Bij deze groep nam de mediane Lp(a) toe met 34,9 nmol/L en 56% van hen overschreed de risicodrempel van ≥125 nmol/L, vergeleken met 28–29% bij vrouwen die wel of niet in de menopauze terechtkwamen. Dit onderstreept dat een eenmalige Lp(a)-bepaling in het leven niet volstaat; herhaling tijdens de menopauze is aan te raden om risicoherschikking en tijdige interventie mogelijk te maken.

## English: Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition.

An observational study of 4,562 UK Biobank women demonstrates that the menopausal transition significantly elevates lipoprotein(a) [Lp(a)] levels, particularly in those with intermediate baseline concentrations (75–125 nmol/L). In this subgroup, median Lp(a) rose by 34.9 nmol/L, and 56% crossed the high-risk threshold of ≥125 nmol/L, compared with 28–29% in women who remained pre- or postmenopausal. These findings suggest that a single lifetime Lp(a) measurement may miss important reclassification, supporting routine retesting during the menopausal transition to refine cardiovascular risk assessment and guide preventive therapy.

## Abstract (original, from the publication)

AIM: Assess changes in Lp(a) levels and transitions across ASCVD risk-thresholds by menopausal trajectory to inform risk stratification and testing recommendations. . METHODS: We examined changes in Lp(a) between visits 1 and 2 among UK Biobank women. Analyses were examined by menopausal trajectory: those who underwent menopause (N=415), those who remained premenopausal (N=532), and those who remained postmenopausal (N=3,615) between visits. Change in Lp(a) between visits was also stratified by visit 1 Lp(a). The primary outcome was incident Lp(a) ≥125 nmol/L at visit 2, estimated using Poisson regression. RESULTS: Data were available for 4,562 women (mean visit 1 age = 57 years; median visit 1 Lp(a) = 22 nmol/L; median time between visits = 4 years). At visit 1, median Lp(a) was 23 nmol/L in postmenopausal women and 19 nmol/L in premenopausal women. Overall, median changes in Lp(a) between visits were modest. Among women with intermediate visit 1 Lp(a) (75-125 nmol/L), those who transitioned through menopause experienced a median increase of 34.9 nmol/L, approximately fourfold greater than women who remained pre- or postmenopausal. Further, 22 of 39 (56%) of women with intermediate visit 1 Lp(a) who had menopause between visits had incident Lp(a) ≥125 nmol/L at visit 2, compared with 29% and 28% of women who remained pre- or postmenopausal, representing a risk ratio of 2.27 (95% CI: 1.36, 3.78) after adjustment for visit 1 age and continuous Lp(a). CONCLUSIONS: Relying on a single lifetime Lp(a) measurement may miss reclassification across risk-enhancing thresholds during menopause, particularly for women with intermediate premenopausal levels.

Auteurs: Catherine A Palmer, Christy L Avery, Christie M Ballantyne, Misa Graff, Ron C Hoogeveen, Anne Marie Jukic, Annie Green Howard, Katherine M Conners

---
Bron: European journal of preventive cardiology, https://doi.org/10.1093/eurjpc/zwag496. Bijgewerkt 2026-09-18T01:19:21Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.